Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations

European Journal of Cancer

Volumn 35, Issue SUPPL. 1, 1999, Pages

  Jackman, A L ^a   Kimbell, R ^a   Ford, H E R ^a  

^a CRC C for C T at the I of C R   (United Kingdom)

Author keywords

5 fluorouracil; Chemotherapy; Drug combination; Raltitrexed

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; COLON CARCINOMA; CONFERENCE PAPER; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033103892     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00041-6     Document Type: Conference Paper

References (30)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
2. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
3. Jackman A.L., Taylor G.A., Calvert A.H., Harrap K.R. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol. 33:1984;3269-3275.
4. Jackman A.L., Farrugia D.C., Gibson W.et al. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer. 31A:1995;1277-1282.
5. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1990;1715-1720.
6. Aherne G.W., Ward E., Lawrence N.et al. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. Br. J. Cancer. 77:1998;221-226.
7. Beale P., Judson I., Hanwell J.et al. Metabolism, excretion and pharmacokinetics of a single dose of [14]-C raltitrexed in cancer patients. Cancer Chemother. Pharmacol. 42:1998;71-76.
8. Cunningham D., Zalcberg J., Smith I.et al. `Tomudex' (ZD 1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann. Oncology. 7:1996;179-182.
9. Cunningham D. Mature results from three large controlled studies with raltitrexed (`Tomudex'). Br. J. Cancer. 77(Suppl. 2):1998;15-21.
10. Jackman A.L., Taylor G.A., Gibson W.et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res. 51:1991;5579-5586.
11. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:1989;215-237.
12. Harstrick A, Schleucher N, Gonazales A, et al. Interactions and cross-resistance patterns between various schedules of 5-FU and the new, folate-based thymidylate synthase inhibitor Tomudex (D1694). Eur J Cancer 1995, 31A(Suppl. 5), S30 (abstract 126).
13. Danenberg K, Salonga D, Park JM, et al. DPD and TS gene expression identify a high percentage of colorectal tumours responding to 5-FU. Proc Amer Soc Clin Oncol 1998, 17, 258 (abstract 992).
14. Poon M.A., O'Connell M.J., Wieand H.S.et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9:1991;1967-1972.
15. Machover D., Goldschmith E., Chollet P.et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid J. Clin. Oncol. 4:1986;685-696.
16. De Gramont A., Bosset J.F., Milan C.et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J. Clin. Oncol. 15:1997;808-815.
17. Grem J.L. Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin. Semin. Oncol. 24(Suppl. 18):1997;8-18.
18. Van der Wilt CL, Pinedo HM, Kuiper CM, et al. Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc Amer Assoc Cancer Res 1995, 36, 379 (abstract 2260).
19. Longo G.S.A., Izzo J., Chang Y.M.et al. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin. Cancer Res. 4:1998;469-473.
20. Van der Wilt CL, Kuiper CM, Pinedo HM, et al. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. In Pfleiderer W, Rokos H, eds. Proceedings of `Chemistry and Biology of Pteridines and Folates, 1997'. Berlin, Blackwell Wissenschafts-Verlag, 1997, 245-248.
21. Shimada Y., Yoshino M., Wakui A.et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11:1993;909-913.
22. Conti J.A., Kemeny N.E., Saltz L.B.et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 14:1996;709-715.
23. Ratain MJ. New agents for colon cancer: Topoisomerase I inhibitors. In Perry MC, ed. American Society of Clinical Oncology Educational Book. 34th Annual Meeting of the American Society of Clinical Oncology, California, 1998, 311-315.
24. Kimbell R, Jackman AL. In vitro studies with ZD1694 (Tomudex) and SN38 in human colon tumour cell lines. In Pfleiderer W, Rokos H, eds. Proceedings of `Chemistry and Biology of Pteridines and Folates, 1997'. Berlin, Blackwell Wissenschafts-Verlag, 1997, 249-252.
25. Aschele C., Baldo C., Sobrero A.F., Debernardis D., Bornmann W.G., Bertino J.R. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin. Cancer Res. 4:1998;1323-1330.
26. Becouarn Y, Ychou M, Ducreux M, et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: Preliminary activity/toxicity report. 33rd Annual Meeting of the American Society of Clinical Oncology 1997, abstract 804.
27. Ratain MJ. Pharmacology of cancer chemotherapy. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, 375-512.
28. Ackland SP, Kimbell R. Antifolates in combination therapy. In Jackman AL, ed. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, Humana, in press, 365-383.
29. Kelland L.R., Kimbell R., Hardcastle A., Aherne G.W., Jackman A.L. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur. J. Cancer. 31A:1995;981-986.
30. Kimbell R, Brunton L, Jackman AL. Combination studies with Tomudex and 5-fluorouracil in human colon tumour cell lines. Br J Cancer 1996, 73(Suppl. 26), 29 (abstract P12).